✦ LIBER ✦

Caution is required with Interferon α as a potential treatment for Type I diabetes

Book ID: 113017907
Publisher: Springer
Year: 1999
Tongue: English
Weight: 28 KB
Volume: 42
Category: Article
ISSN: 0012-186X
DOI: 10.1007/s001250051170

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Fasiglifam as a new potential treatment

Fasiglifam as a new potential treatment option for patients with type 2 diabetes

✍ Kaku, Kohei 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 635 KB

High incidence of type 1 diabetes mellit

High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon α for chronic hepatitis C virus infection

✍ Tim C. M. A. Schreuder; Huub C. Gelderblom; Christine J. Weegink; Dörte Hamann; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB

Hazara virus infection is lethal for adu

Hazara virus infection is lethal for adult type I interferon receptor-knockout mice and may act as a surrogate for infection with the human-pathogenic Crimean-Congo hemorrhagic fever virus

✍ Rayner, E.; Pearson, G.; Pickersgill, J.; Rule, A.; Merredew, N.; Smith, H.; Cha 📂 Article 📅 2012 🏛 Society for General Microbiology 🌐 English ⚖ 438 KB

Apoptosis of Autoreactive CD8 Lymphocyte

Apoptosis of Autoreactive CD8 Lymphocytes as a Potential Mechanism for the Abrogation of Type 1 Diabetes by Islet-Specific TNF-α Expression at a Time When the Autoimmune Process Is Already Ongoing

✍ URS CHRISTEN; MATTHIAS G. VON HERRATH 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 773 KB

[RSC Drug Discovery] New Therapeutic Str

[RSC Drug Discovery] New Therapeutic Strategies for Type 2 Diabetes Volume 74 || Chapter 11. The Discovery and Development of MB07803, a Second-Generation Fructose-1,6-bisphosphatase Inhibitor with Improved Pharmacokinetic Properties, as a Potential Treatment of Type 2 Diabetes

✍ Jones, Rob M 📂 Article 📅 2012 🏛 Royal Society of Chemistry ⚖ 720 KB

Weight loss with liraglutide, a once-dai

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

✍ J. Jendle; M. A. Nauck; D. R. Matthews; A. Frid; K. Hermansen; M. Düring; M. Zdr 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 579 KB